Published in J Clin Psychopharmacol on April 01, 2010
Pharmacotherapy for treatment-resistant schizophrenia. Neuropsychiatr Dis Treat (2011) 0.89
The Effect of Small Molecules on Sterol Homeostasis: Measuring 7-Dehydrocholesterol in Dhcr7-Deficient Neuro2a Cells and Human Fibroblasts. J Med Chem (2016) 0.77
Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry (2002) 5.14
Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry (2002) 2.52
Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry (2003) 1.76
Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry (2006) 1.74
The InterSePT scale for suicidal thinking reliability and validity. Schizophr Res (2003) 1.58
Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Psychiatr Res (2011) 1.57
Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychopharmacol (2004) 1.23
Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor. CNS Drug Rev (2006) 1.08
Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychiatry (2004) 1.04
The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia. Neurosci Lett (2005) 1.02
Gender differences in violent behaviors: relationship to clinical symptoms and psychosocial factors. Am J Psychiatry (2004) 1.00
Aggression and psychopathology in treatment-resistant inpatients with schizophrenia and schizoaffective disorder. J Psychiatr Res (2005) 0.98
Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol. Schizophr Res (2009) 0.97
Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study. J Clin Psychiatry (2002) 0.95
Placebo or active control trials of antipsychotic drugs? Arch Gen Psychiatry (2003) 0.90
Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia. J Clin Psychiatry (2004) 0.89
Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients. J Clin Psychopharmacol (2008) 0.89
Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST). J Clin Psychiatry (2011) 0.88
Suggestive association between the C825T polymorphism of the G-protein beta3 subunit gene (GNB3) and clinical improvement with antipsychotics in schizophrenia. Eur Neuropsychopharmacol (2005) 0.86
DOV 216,303, a "triple" reuptake inhibitor: safety, tolerability, and pharmacokinetic profile. J Clin Pharmacol (2004) 0.86
Suicide attempts and family history of suicide in three psychiatric populations. Suicide Life Threat Behav (2005) 0.85
Effectiveness of clozapine, olanzapine, quetiapine, risperidone, and haloperidol monotherapy in reducing hostile and aggressive behavior in outpatients treated for schizophrenia: a prospective naturalistic study (IC-SOHO). Eur Psychiatry (2005) 0.83
COMT158 polymorphism and hostility. Am J Med Genet B Neuropsychiatr Genet (2004) 0.82
Efficacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder: data from 5 double-blind studies. J Clin Psychiatry (2005) 0.82
Early sensory-perceptual processing deficits for affectively valenced inputs are more pronounced in schizophrenia patients with a history of violence than in their non-violent peers. Soc Cogn Affect Neurosci (2012) 0.82
Visual sensory processing deficits in schizophrenia: is there anything to the magnocellular account? Schizophr Res (2012) 0.82
Efficacy of ziprasidone against hostility in schizophrenia: Post hoc analysis of randomized, open-label study data. J Clin Psychiatry (2006) 0.81
Family and case-control association study of the tumor necrosis factor-alpha (TNF-alpha) gene with schizophrenia and response to antipsychotic medication. Psychopharmacology (Berl) (2006) 0.81
Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility. Int Clin Psychopharmacol (2007) 0.80
Cholesterol and cognition in schizophrenia: a double-blind study of patients randomized to clozapine, olanzapine and haloperidol. Schizophr Res (2011) 0.80
Executive function predicts response to antiaggression treatment in schizophrenia: a randomized controlled trial. J Clin Psychiatry (2011) 0.80
Course of patients with histories of aggression and crime after discharge from a cognitive-behavioral program. Psychiatr Serv (2004) 0.80
Psychosocial risk factors associated with suicide attempts and violence among psychiatric inpatients. Psychiatr Serv (2004) 0.79
Identification of a naturally occurring 21 bp deletion in alpha 2c noradrenergic receptor gene and cognitive correlates to antipsychotic treatment. Pharmacol Res (2005) 0.78
Adverse reactions to duloxetine in depression. Expert Opin Drug Saf (2011) 0.77
A cognitive, behaviorally based program for patients with persistent mental illness and a history of aggression, crime, or both: structure and correlates of completers of the program. J Am Acad Psychiatry Law (2005) 0.75
Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation. Schizophr Res (2004) 0.75
The denial of aggression in violent patients with schizophrenia. Schizophr Res (2012) 0.75
Suicide and violence in patients with major psychiatric disorders. J Psychiatr Pract (2004) 0.75